trovirdine and Disease-Models--Animal

trovirdine has been researched along with Disease-Models--Animal* in 1 studies

Other Studies

1 other study(ies) available for trovirdine and Disease-Models--Animal

Article	Year
Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 1995, Aug-29, Volume: 92, Issue:18 The reverse transcriptase (RT) of the human immunodeficiency virus type 1 (HIV-1) is the major target for antiretroviral therapy of the acquired immunodeficiency syndrome (AIDS). While some inhibitors exhibit activity against most retroviral RTs, others are specific for the HIV-1 enzyme. To develop an animal model for the therapy of the HIV-1 infection with RT inhibitors, the RT of the simian immunodeficiency virus (SIV) was replaced by the RT of HIV-1. Macaques infected with this SIV/HIV-1 hybrid virus developed AIDS-like symptoms and pathology. The HIV-1-specific RT inhibitor LY300046.HCl, but not zidovudine [3'-azido-3'-deoxythymidine (AZT)] delayed the appearance of plasma antigenemia in macaques infected with a high dose of the chimeric virus. Infection of macaques with the chimeric virus seems to be a valuable model to study the in vivo efficacy of new RT inhibitors, the emergence and reversal of drug resistance, the therapy of infections with drug-resistant viruses, and the efficacy of combination therapy. Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Animals; Antiviral Agents; Base Sequence; Cell Line; Disease Models, Animal; DNA Primers; HIV Reverse Transcriptase; HIV-1; Macaca fascicularis; Macaca mulatta; Molecular Sequence Data; Pyridines; Reverse Transcriptase Inhibitors; Simian Immunodeficiency Virus; Zidovudine	1995

Article

Year

Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.

Proceedings of the National Academy of Sciences of the United States of America, 1995, Aug-29, Volume: 92, Issue:18

The reverse transcriptase (RT) of the human immunodeficiency virus type 1 (HIV-1) is the major target for antiretroviral therapy of the acquired immunodeficiency syndrome (AIDS). While some inhibitors exhibit activity against most retroviral RTs, others are specific for the HIV-1 enzyme. To develop an animal model for the therapy of the HIV-1 infection with RT inhibitors, the RT of the simian immunodeficiency virus (SIV) was replaced by the RT of HIV-1. Macaques infected with this SIV/HIV-1 hybrid virus developed AIDS-like symptoms and pathology. The HIV-1-specific RT inhibitor LY300046.HCl, but not zidovudine [3'-azido-3'-deoxythymidine (AZT)] delayed the appearance of plasma antigenemia in macaques infected with a high dose of the chimeric virus. Infection of macaques with the chimeric virus seems to be a valuable model to study the in vivo efficacy of new RT inhibitors, the emergence and reversal of drug resistance, the therapy of infections with drug-resistant viruses, and the efficacy of combination therapy.

Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Animals; Antiviral Agents; Base Sequence; Cell Line; Disease Models, Animal; DNA Primers; HIV Reverse Transcriptase; HIV-1; Macaca fascicularis; Macaca mulatta; Molecular Sequence Data; Pyridines; Reverse Transcriptase Inhibitors; Simian Immunodeficiency Virus; Zidovudine

1995